| Project/Area Number |
19K08691
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53040:Nephrology-related
|
|---|
| Research Institution | Fujita Health University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
湯澤 由紀夫 藤田医科大学, 医学部, 教授 (00191479)
坪井 直毅 藤田医科大学, 医学部, 教授 (50566958)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2021: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | IgA腎症 / 糖鎖異常IgA / バイオマーカー / 質量分析 / 糖鎖医学 / 糖鎖異常IgA1 / 迅速診断法 / プロテオミクス |
|---|
| Outline of Research at the Start |
IgA腎症は，わが国に多い慢性糸球体腎炎で，20年の経過で約40％が末期腎不全に陥る。患者血液中に増加する糖鎖異常IgA1（Gd-IgA1; Gal-deficient-IgA1）は病因に深く関与する。本研究は，本症におけるGd-IgA1の役割の解明と診断への応用を目指し，①IgA腎症患者の沈着IgA1の糖鎖構造を同定，②Gd-IgA1の臨床的意義を検討，③迅速なGd-IgA1検出法の開発を行う。
|
| Outline of Final Research Achievements |
We aimed to develop a Point of Care Testing (POCT) by identifying detailed glycan structure of nephritogenic abnormally glycosylated IgA1 increasing specifically in IgA nephropathy (IgAN). We quantitatively profiled glycoforms of serum IgA1 derived from Japanese and Caucasian patients of IgAN and identified candidate glycoforms that are specifically increased in IgAN. We are currently generating monoclonal antibodies to specific glycoform to develop POCT.
|
| Academic Significance and Societal Importance of the Research Achievements |
日本人と白人のIgA腎症に共通のIgA1の糖鎖構造の特徴を同定した。新規診断薬の開発のみならず，糖鎖異常IgA1の産生機構の解明，さらには新規治療標的につながることが期待される。
|
